Side-by-side comparison

ABT vs GILD — Side-by-side comparison

GILD screens cheaper on EV/FCF, GILD has the higher ROIC, ABT has grown revenue faster over five years, and ABT has the cleaner balance sheet by net debt / EBITDA.

ABT

Abbott Labs

Price

$87.41

Market cap

$230.7B

Day %

N/A

GILD

Gilead Sciences

Price

$134.36

Market cap

$128.0B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


ABT Target	Abbott Labs	$230.7B	23.5x	31.8x	10.0%	5.1%	16.7%	N/A	0.5x	N/A
GILD	Gilead Sciences	$128.0B	19.8x	15.4x	17.9%	3.6%	32.1%	N/A	1.7x	N/A

ABT implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

31.8x

FCF yield

3.2%

5Y rev CAGR

5.1%

GILD implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

15.4x

FCF yield

7.4%

5Y rev CAGR

3.6%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for ABT.

Grade C

/ 100

Quality Radar0 – 20 per axis

Quality Scorecard

Build-time composite score for GILD.

Grade B

/ 100

Quality Radar0 – 20 per axis